CVRx is a medical technology company that develops Barostim, a novel therapeutic device designed to improve symptoms of heart failure. Barostim functions as an implantable device that stimulates baroreceptors to help regulate heart, kidney, and vascular functions, potentially reducing the heart’s workload and improving its efficiency. The therapy has been shown to increase exercise capacity and significantly improve quality of life for patients with heart failure, as compared to standard medical treatments. CVRx focuses on providing this innovative therapy to enhance patient outcomes and quality of life for those suffering from heart failure.